SCHEDULE: FMR LLC Reports Stake in Centessa Pharmaceuticals

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 1,800 shares of Centessa Pharmaceuticals PLC common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of 1,800 shares of Centessa Pharmaceuticals PLC common stock.
• This filing, dated June 30, 2026, represents a 0.0% ownership stake in the company's common stock.
• FMR LLC is classified as an Investment Adviser (IA) and a Holding Company, while Abigail P. Johnson is identified as an Insider (IN).
• The filing confirms that no single other person is known to hold more than a five percent interest in the common stock.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily a routine disclosure of a very small ownership stake with no new financial or strategic information provided.

Positives

• FMR LLC and Abigail P. Johnson have disclosed their holdings, providing transparency to the market.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting no intent to disrupt corporate control.

Negatives

• The reported ownership stake of 1,800 shares represents 0.0% of the class of securities, indicating a very minor holding.
• The filing does not provide any financial performance data or strategic updates for Centessa Pharmaceuticals PLC.

Risks

• The filing does not contain any specific risks related to Centessa Pharmaceuticals PLC's operations or financial health.
• The primary risk associated with this filing is the potential for future changes in beneficial ownership by FMR LLC or Abigail P. Johnson, which could impact the stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Centessa Pharmaceuticals PLC's future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and significant individual holders, indicating changes or confirmations of beneficial ownership. This filing by FMR LLC and Abigail P. Johnson, while reporting a minimal percentage, adds to the transparency of Centessa Pharmaceuticals PLC's shareholder base.

Stakeholder Impact

• Shareholders: Increased transparency regarding a portion of the company's ownership structure.
• Management: No direct impact, as the filing is a standard disclosure and does not indicate any intent to influence control.

Next Steps

• Continued monitoring of future Schedule 13G filings by FMR LLC and Abigail P. Johnson for any changes in their stake in Centessa Pharmaceuticals PLC.

Key Dates

Keywords

Centessa Pharmaceuticals, Schedule 13G, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Holding Company